Research Areas

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC11731	Ruzasvir	A potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively..
DC11710	GDC-0425	A potent, selective and orally active Chk1 inhibitor.
DC11868	Freselestat	A potent, selective and orally active human neutrophil elastase (HNE) inhibitor with Ki of 12 nM.
DC11514	Atogepant	A potent, selective and orally available CGRP receptor antagonist for the prevention of migraine. Migraine.
DC11519	Ceclazepide	A potent, selective cholecystokinin receptor CCK2 antagonist for treatment of gastroesophageal reflux disease (GERD)..
DC11838	Org 25935	A potent, selective glycine transporter 1 (GlyT1) inhibitor with IC50 of 100 nM.
DC11849	DSM421	A potent, selective P. falciparum dihydroorotate dehydrogenase (PfDHODH) with IC50 of 53 nM.
DC11850	MK-7145	A potent, selective, and oral renal outer medullary potassium channel (ROMK) inhibitor with IC50 of 68 nM.
DC11895	Foliglurax hydrochloride	A potent, selective, brain-penetrant and orally bioavailable mGluR4 positive allosteric modulator with EC50 of 79 nM.
DC11894	Foliglurax	A potent, selective, brain-penetrant and orally bioavailable mGluR4 positive allosteric modulator with EC50 of 79 nM.
DC11898	Gosogliptin	A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM.
DC11899	Gosogliptin dihydrochloride	A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM.
DC11721	PF-06747775	A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.
DC11667	PF-592379	A potent, selective, orally active agonist of dopamine D3 receptor with EC50 of 21 nM.
DC11688	Avacopan Featured	Avacopan is a potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM.
DC11716	XL-844	A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.
DCAPI1468	Rosuvastatin Calcium Featured	A selective, competitive inhibitor of HMG-CoA reductase, that is also antilipemic.
DC11525	Mocravimod	A synthetic immunosuppressant that functions as a S1P1 receptor agonist.
DC11491	A-1048400	A-1048400(A 1048400) is a novel potent, selective, orally active N-type and T-type calcium channel blocker with IC50 of 1.4 and 1.2 uM, respectively.
DC11490	A-317567	A-317567 (A317567) is a novel potent acid sensing ion channel (ASIC) blocker with IC50 of 2-30 uM.
DC7351	A-740003	A-740003 is potent, selective and competitive P2X7 receptor antagonist (IC50 values are 18 and 40 nM for rat and human receptors respectively).
DC7045	A-769662 Featured	A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM, little effect on GPPase/FBPase activity.
DC21979	ATF6 agonist compound A147 Featured	ATF6 agonist compound A147 is a specific, small molecule agonist of transcription factor ATF6, activates ATF6 and influences differentiation of stem cells.147 has broad antiviral activity against multiple DENV strains and serotypes and that the compound i
DC10797	AB-423 Featured	AB-423 is the first-generation Hepatitis B Virus Capsid Assembly inhibitor, which was generally safe and well tolerated in Phase 1 healthy volunteer studies.
DC9029	Abacavir	Abacavir is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.
DC11452	ABBV-744 Featured	ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.BBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.
DC5027	ABC294640（Opaganib） Featured	ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity.
DC2710	Abiraterone (CB-7598)	Abiraterone (CB-7598) is a potent CYP17 inhibitor with IC50 of 2 nM.
DC4127	ABT-263 (Navitoclax) Featured	ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.
DC9706	ABT-639 Featured	ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM).

Research Areas

Customized Consultation X

Your information is safe with us. * Required Fields.